

INDEX

A

Abruptex..... 6, 45
 Actin cytoskeleton (F-actin)..... 68, 69, 72
 Adeno-associated virus (AAV)..... 118, 120, 127, 128
 A disintegrin and metalloproteinase
 (ADAM) 5, 7, 9, 87, 323, 326, 335
 ADAM10 311
 Affinity purification..... 182, 183, 186–188,
 190, 281
 After Puparium Formation (APF) 81
 Alkaline lysis 35, 37
 Alkaline phosphatase (AP) 278–283
 Allosteric inhibitor 315, 316
 Alzheimer's disease (AD) 2, 223, 312, 314–316
 American Type Culture Collection (ATCC)..... 336
 Amino acid..... 56, 65, 66, 88, 194, 196,
 201, 203, 205, 210, 220, 224, 232
 Ammonium Persulfate (APS)..... 235, 237
 Ampicillin resistance (Ap^R) 32–38, 44
 Amyloid precursor protein (APP) 248, 312, 314, 316
 Aβ40 315
 Aβ42 315
 β-APP 312
 Analytical ultracentrifugation 233
 Anesthetizer 19
 Ankyrin repeat (ANK) 7, 157, 231, 232, 243
 Antibody
 activating 324–326, 331
 blocking 335, 336
 high affinity 88
 inhibitory 324–326
 low affinity 102, 110
 monoclonal 10, 83, 89, 104, 194
 polyclonal 69
 primary 63, 69, 70, 72, 75, 76,
 80, 83, 97, 106–108, 110, 111, 227
 secondary/fluorescent conjugated 63, 69, 70,
 72, 74, 80, 83, 89, 97, 106, 107, 109, 111, 224, 227
 uptake 95
 uptake assay 79–85, 88–90, 95–97
 Apoptosis..... 18, 252, 317, 319
 Arylsulfonamides..... 316
 Aspartyl protease 314
 Assay
 binding 193, 277–283
 cell-based 225, 318

 dual-luciferase..... 138, 150, 325–327, 337, 338
 endocytosis 80
 GSI-washout 247–252
 luciferase 134, 135, 138, 140,
 148, 150, 151, 325–329, 331, 332, 337–338
 Asymmetric cell division 79
 pIIa/pIIb..... 79, 84

B

Bacterial artificial chromosome (BAC)..... 32, 34,
 35, 55, 81, 85
 Bacterial attachment site (attB) 33, 34, 38
 Balancer..... 22, 24, 42
 Basic Helix Loop Helix (bHLH) 102–104, 110
 BDGP. *See* Berkeley *Drosophila* Genome Project (BDGP)
 BDSC. *See* Bloomington *Drosophila* Stock Center
 (BDSC)
 Bearded/bearded family..... 102
 Benzoazepinone 315
 Berkeley *Drosophila* Genome Project
 (BDGP)..... 182, 184, 190
 βME. *See* β-Mercaptoethanol (βME)
 bHLH. *See* Basic Helix Loop Helix (bHLH)
 Binding..... 6–9, 49, 54, 55, 57, 81, 85,
 87, 88, 92, 98, 102, 103, 110, 111, 117, 133, 134,
 144–146, 155–157, 190, 193–195, 203–206, 209,
 231–235, 237, 238, 242, 248, 256, 257, 263, 269,
 270, 274, 277–283, 315, 316, 323–326, 328, 335
 Bioinformatics/bioinformatic analysis 9, 182, 184,
 188–189, 206, 266, 267, 274–275
 Bioluminescence 159–165, 170–177
 Biotin/biotinylation/biotin-avidin 88–94, 98,
 196, 200, 207, 233
 Bi-transgenic Notch1 reporter 55
 Blood–brain barrier 325
 Bloomington *Drosophila* Stock Center
 (BDSC) 19, 23, 33, 107
 Bovine serum albumin (BSA)..... 69, 70, 90, 107,
 177, 212, 220, 226, 229, 235, 280–282
 BTD. *See* β-Trefoil domain (BTD)..... 231, 232

C

Caenorhabditis elegans 2, 3, 9, 312
 Calcium/Ca²⁺
 binding 195, 203, 204, 206
 chelation 147, 149, 152, 159, 165

- Calcium chelator
 1,2-bis(o-aminophenoxy)ethane-*N,N,N,N'*-tetraacetic acid (BAPTA)..... 152, 166, 204
 ethylene diamine tetraacetic acid (EDTA)..... 131, 132, 134, 136–137, 139, 140, 152, 166, 172, 174–175, 183, 195, 196, 198, 206, 234, 236, 238, 240, 242, 259–262, 265, 329
 ethylene glycol tetraacetic acid (EGTA)..... 131, 132, 134, 136–137, 139, 140, 147, 149, 152, 159, 164–166, 197, 200, 201, 207, 228, 259–261
- Carboxy-terminus (C-terminus) 7, 205, 224
- Carcinogenesis.....255
- cbEGF.....195, 200, 201, 203, 204
- CBF1.....54, 115–117, 127, 324
- Cell culture media
 CCM3279–281
 DMEM/F12171, 172, 174–176, 225–228
 Dulbecco's modified Eagle's medium (DMEM).....88, 91, 93–95, 158, 159, 171–176, 225–228, 328, 336
 M3 complete medium279–281
 N2 and B27 medium 172, 175, 176
 Opti-MEM 135, 137, 138, 140, 212, 213, 329, 332
 T6E249, 250
- Cell death 3, 140, 155
- Cell fate decisions.....3
- Cell lethal (*cl*) 19, 22
- Cell lines
 CHO-Dll1-IRES-GFP (hamster)147, 159
 CHO-Jag1-IRES-GFP (hamster)159
 CHO-Notch2 (hamster)147
 HEK/HEC293T/293T (human) 147, 151, 166, 224–228
 human umbilical endothelial cells (human) (HUVEC)336, 337
 Kc167 (*Drosophila*)..... 134, 189
 ligand expressing cells..... 88, 133, 145, 147, 149, 159, 326, 328, 330, 331, 341
 murine embryonic fibroblast/primary fibroblast (mouse)..... 88, 89, 96, 124
 OP9 (mouse) 88, 327, 328
 OP9-delta (mouse).....252
 receptor expressing cells.....55, 341
 Schneider 2 (*Drosophila*)..... 133
 S2R + (*Drosophila*) 182, 184, 185, 189
 3T3 (mouse) 146, 151, 318, 328
 T6E (human).....249–251
 3T3-L1 (mouse).....145
 U2OS (human)..... 88, 328, 329, 332
- Cell surface..... 3, 5, 6, 8, 57, 85, 87–95, 330, 331
- Cell-to-cell communication115
- Central nervous system (CNS).....110, 316
- Charge-coupled device (CCD).....167, 170
- Chemiluminescence.....233
- Chimeric Notch receptor.....146, 158
- Chromatin.....7, 9, 10, 248, 255–258
- Chromatin immunoprecipitation (ChIP)
 ChIP-Seq257, 266–275
 cross-linking ChIP 256, 257, 262–264, 272
 native ChIP256, 257, 264–266, 272, 273
- Chromosome.....17–19, 22, 24, 25, 35, 39–42, 44, 51, 55, 81, 106, 107, 268
- Circular dichroism.....233
- Cis*-interactions..... 8, 286, 300, 303
- Cistrome.....257, 266–272, 274, 275
- Cleavage
 S1.....5, 6
 S2..... 5–9, 224, 311, 312
 S3..... 5–8, 224, 225, 248, 249, 311
- Clinical trial..... 223, 315, 336
- Coactivators
 CREB-binding protein (CBP).....232
 E1A binding protein p300232
- Co-culture145, 149, 150, 161, 165, 327, 329–331, 341
- Collier model.....287–307
- Collision induced dissociation (CID).....211, 216–219
- Complementation imaging.....155–168
- Conditional33, 35, 47–53, 56, 325
- Conditionally amplifiable origin of replication (*oriV*).....33
- Conditional mutant mice
 gain-of-function48–54
 loss-of-function48–54
- Conditioned medium151, 164, 166, 167, 279–283
- Confluens 39–41, 45, 95, 98, 137, 140, 160, 161, 165, 178, 185, 213, 226, 228, 279–281, 329, 330, 338, 341
- Confocal microscopy 68, 74, 83, 97
- Conformational change.....5–8, 335
- Context dependent 23, 115, 247
- Context specific.....2, 9, 247
- Cooperativity.....290, 292, 303
- Copy control solution..... 32, 35, 37
- Copy number variation (CNV)10
- Corepressors
 CIR.....232
 KyoT2/FHL1232, 256
 MINT/SHARP232
 SKIP232
 SMRT232
- Cosmid.....30
- Cre driver49–51
- Cre-Lox system48–50, 53
- Cre recombinase48–50, 55, 56
- Cre recombinase-estrogen receptor fusion protein53
- Cre recombinase fused to mutant estrogen ligand-binding domain (CreERT2)55, 56
- CSL CBF1/suppressor of hairless/Lag-1
 binding site144–146, 257, 270, 325, 326
 N-terminal Rel-homology region (NTD)231, 232
- C-terminal Binding Protein (CtBP)7

C-terminal Rel-homology region (CTD)231, 232
 Cultured cells. *See* Cell lines
 CuSO₄ induction182
 Cut 44, 66, 71, 83, 101, 102, 104, 173
 Cyclin-dependent kinase-8 (CDK8)7
 Cycloheximide 249, 250, 252, 270

D

Deacetylases7, 256
 Decoy7
 Degradation 6–10, 88, 91, 92, 95–97, 99, 110, 111, 117, 207, 287, 288, 290, 291, 295
 Delta/serrate/LAG-2 (DSL)
 delta (DI)65, 80, 82, 83, 85, 282
 delta-like ligand 1 (Dll1) 6, 49, 88–90, 92, 98, 147, 159, 323, 327, 328, 331, 335–337, 341
 delta-like ligand 3 (Dll3) 6, 7, 335
 delta-like ligand 4 (Dll4) 6, 49, 323, 326, 328, 331, 335–341
 domain335
 Development 1–4, 8–10, 15, 18, 23, 41, 43, 47, 49, 52, 54, 56, 57, 59, 66, 68, 69, 71, 75, 79, 80, 89, 95, 101, 102, 104, 106, 110, 115, 156, 167, 181, 223, 238, 247, 248, 285, 312, 314, 316, 324
 Developmental Studies Hybridoma Bank (DSHB)65–70, 80, 89, 95, 104
 4',6-Diamidino-2-phenylindole (DAPI)69
 1,4-Diazabicyclo[2.2.2]octane (DABCO) 70, 75, 90
 Diethylpyrocarbonate (DEPC)135
 Differentiation 3, 18, 56, 169, 255, 285, 307
 Diseases
 angiogenesis318, 336
 cancer3, 8, 47, 184, 223, 312, 314–319, 325, 336
 carcinogenesis225
 cardiometabolic syndromes339
 congenital disorders1
 hematopoietic malignancies335
 hereditary47
 idiopathic47
 neurological2
 non-small cell lung carcinoma (NSCLC)319
 psychiatric2
 solid tumors 315–317, 336
 stroke1
 T cell acute lymphoblastic leukemia (T-ALL) 9, 248, 256, 316–318, 323–325
 tumor 2, 56, 315, 316, 318, 319, 325, 336
 Dithiothreitol (DTT)89, 148, 151, 194, 198, 200, 206, 212, 234, 235, 238–242, 259–261, 273
 DNA-binding domain144, 146
 DNA labeling
 biotinylated DNA233
 chemiluminescent detection233
 fluorescently labeled DNA233

intercalating fluorescent dyes233
 radioactive labeling, isotopic DNA labeling233
 DNA methylation255
 Docking site 32, 34, 38–41, 45, 314, 315
 Domain-swap56–57
 Dominant negative49, 106, 107, 117, 145, 147
 Dominant negative MAML (DNMAML).
 See Mastermind-like (MAML)
 Dorsal-ventral boundary 101, 105
 Dosage-sensitive 4, 30
 Doxycycline (Dox) 158, 165, 167
Drosophila development
 adult40–43, 45, 101, 103, 104
 bristle 79, 81
 embryo 18, 38, 42
 larva 43, 64, 81
 metamorphosis79, 81
 pupa 43, 45, 81–85
Drosophila melanogaster 15, 30, 63–76, 318
 Drug9, 10, 50, 145, 248, 249, 312, 316, 328, 330
 Drug target2, 9
 Dual-luciferase assay 138, 326, 338

E

EDTA/EGTA treatment 132, 136–137, 139, 140
 EEA195
 EGF domain-specific O-linked N-acetylglucosamine (GlcNAc) transferase (EOGT)210
 EGF repeats. *See* Epidermal growth factor like repeats (EGFr)
 Electrophoretic mobility shift assay (EMSA)231–243
 Electrospray ionisation mass spectrometry (ESI-MS)207
 E3 ligase6
 Embryo 1, 18, 38, 42, 52, 55, 58, 104, 118–119, 121–122, 124, 125, 127, 170–178, 189
 Embryogenesis48
 Embryonic stem cell (ES cell)48, 57
 Endocytosis/endocytic. *See also* Vesicle/vesicular trafficking
 trans-endocytosis5, 6, 8
 Endogenous Notch responsive genes 102, 232, 255
 Endolysosomal pathway8
 Endoplasmic reticulum (ER)4–6
 Endothelial Cell Growth Supplement (ECGS)337
 Enhancer 16, 30, 45, 48, 81, 103, 104, 131, 133, 134, 137, 140, 257, 270, 312
 Enhancer of Split (*E(spl)*) 2, 102–105, 110, 132, 134, 135, 139, 248
 Epidermal growth factor-like (EGF) 4, 31, 32, 34, 36, 38, 40, 69, 80, 88, 89, 95–97, 171, 172, 194, 201, 206, 210–212, 216–219, 281, 283, 304, 335
 Epidermal growth factor like repeats (EGFr) 4–6, 31, 32, 34, 36–38, 40, 69, 80, 95, 210–212, 216–219
 Epigenetic(s)255–275

<i>Escherichia coli</i>	
BL21.....	197, 205
EPI300.....	35, 37
SW102.....	35–37
Ethyl methanesulfonate (EMS).....	15–25
mutagenesis.....	16–22
European Conditional Mouse Mutagenesis Program (EUCOMM).....	49
Exocytosis/exocytic. <i>See</i> Vesicle/vesicular trafficking	
Experimental approaches.....	233
Extracellular.....	2, 4, 6–8, 32, 57, 63, 65, 69, 80, 89, 107, 159, 209, 210, 224, 248, 278, 281, 311, 335
Extracellular domain (ECD).....	4, 6–8, 32, 57, 63, 69, 80, 89, 107, 159, 209–213, 224, 248, 278, 281, 335
Extracted ion chromatograms (EIC).....	211, 217–219
Ex vivo.....	54, 80
F	
Fast protein liquid chromatography (FPLC).....	239
Fate mapping.....	55–56, 116, 117
Filopodia.....	286, 303, 307
Fine-tune.....	4, 9, 10
Fixation.....	68–72, 75, 80, 82, 83, 89, 96, 122
Flippase (FLP).....	17–19, 48, 106
Flippase recognition target (FRT).....	17–19, 48, 106, 161, 167
Flow cytometry.....	54, 205
Floxed, flox.....	49–51, 128
FLP/FRT system.....	17
Fluorescent proteins	
green (GFP)	
EGFP.....	54, 58, 103, 105, 116–118, 121, 122, 127, 128, 145, 189
emGFP.....	54
red (RFP)	
DsRed.....	121
mCherry.....	103, 105, 106, 145
tomato.....	56
yellow (YFP).....	53, 58
venus.....	54, 58, 103, 105, 106
Fly/flies. <i>See</i> <i>Drosophila melanogaster</i>	
Fringe	
Lunatic.....	4
Manic.....	4
Radical.....	4
F1 screen.....	18
Furin-like convertase.....	311
Furin-like protease.....	5, 6
G	
Gain-of-function.....	16, 29, 39, 45, 48–54, 248, 324
β -Galactosidase.....	54, 56, 106, 111, 150, 153, 332
<i>Gal80ts</i>	106
GAL4/UAS binary expression system.....	16
Gal4VP16 transcriptional activator (Gal4VP16).....	55
Gamma secretase (γ -secretase)	
activity.....	2
anterior pharynx 1 A/B (Aph1A/B).....	312
inhibitor (<i>see</i> γ -Secretase inhibitor (GSI))	
nicastrin (NCT).....	312
presenilin 1/2 (PS1/2).....	312
presenilin enhancer 2 (Pen2).....	312
Gap-repair mutagenesis.....	34, 36
Gastrointestinal toxicity. <i>See</i> Intestinal/gastrointestinal/ gut toxicity	
Gel electrophoresis (DNA).....	33, 233, 234, 272
Gel electrophoresis (protein).....	93, 94, 98, 183, 199–201, 206, 207, 214, 220, 225
native (non-denaturing).....	233
Gene synthesis.....	36–38
Genetic interactions.....	39, 181, 191
Genetic screen.....	2, 9, 15–25, 31, 181, 312
Genome.....	9, 16, 17, 20, 22–24, 31–34, 44, 48, 49, 51, 57–59, 181, 182, 184, 257, 266–269, 274, 275, 312
Genomic rescue transgene, genomic transgene.....	29–45
<i>gfp-1</i>	2
Glucocorticoid.....	317, 319
Glycan.....	209–211, 216–219
Glycosylation.....	8, 31, 194, 209, 211
Golgi complex.....	4–6
Grainyhead.....	102, 133
Groucho.....	7
Gut toxicity. <i>See</i> Intestinal/gastrointestinal/gut toxicity	
H	
Halorhodopsin.....	118, 128
Hank's balanced salt solution (HBSS).....	139, 147, 150, 159, 164, 165, 278, 280, 282
Haploinsufficient.....	3, 41–42
HERP family	
<i>Hey1</i>	247, 251, 340
<i>Hey2</i>	247, 340
<i>HeyL</i>	247
HES family.....	102, 248
Hes genes	
<i>Hes1</i>	54, 117, 145, 146, 169–178, 247, 251, 340
<i>Hes7</i>	169, 170, 172–174, 178
Heterodimer.....	8, 312
Heterodimerization domain (HD domain).....	6, 9
High performance liquid chromatography (HPCLC).....	195, 198
Hill-type functions.....	287
Hippocampus.....	124, 128
Histone.....	7, 54, 255–258, 269, 270, 273
Histone acetyltransferases (HAT).....	7, 256
Histone deacetylase (HDAC).....	7, 256, 273
HDAC1.....	256
Histone demethylases.....	256
KDM5A.....	256
Histone methyltransferases.....	255

Hoechst 3334290
 Homeostasis 47, 101, 317
 Homolog 2, 4, 325
 Hydrogen exchange coupled mass spectrometry233

I

IC₅₀.....315–318
 Imaginal disc
 eye-antennal disc71, 73
 wing disc.....73
 Imaging
 confocal74, 81, 84
 live 55, 80, 83–85, 156–158, 161, 162
 molecular 155, 171, 339
 real-time163
 Immobilized ligand 149, 150, 161, 167
 Immunoblot.....225, 227
 Immunoglobulin (Ig).....278, 330
 Immunohistochemistry 63, 72, 122, 124
 Immunostaining68, 70, 72, 89, 105–109, 170
 IMSR. *See* International Mouse Strain Resource (IMSR)
 Inclusion bodies.....194, 241–242
 Inductive signaling3
 In silico..... 9, 220, 286
 In situ106, 170
 Interaction
 cis.....8, 286, 300, 303
 protein–DNA233, 234
 protein–protein.....9, 155, 189, 191, 233
 trans.....285, 288, 301, 307
 Interactome181–191
 Internalization/internalized 80, 82–85, 87, 88, 90, 92, 95–99
 Internal ribosome entry site (IRES)53
 International Mouse Strain Resource (IMSR)57, 58
 Intestinal/gastrointestinal/gut toxicity 317, 319, 324, 325
 Intracellular
 domain.....2, 3, 6, 7, 53, 55–57, 63, 69, 117, 132, 144, 159, 169, 209, 223, 248, 285, 311, 323, 335, 340
 trafficking79–85, 87
 Intracranial viral injection..... 118, 120, 124, 128
 Intramembrane7, 55, 87
 Intraventricular electroporation 118–119, 122, 124–128
 In utero electroporation 120–122, 124, 127–128
 In vitro 8, 10, 54, 84, 124, 193–207, 248, 252, 281–282, 313, 318, 319, 325, 335, 338–339
 In vivo7–10, 16, 23, 30–32, 54–58, 79–85, 101–111, 120, 124, 248, 313, 318, 319, 335, 339–340
 Ion-exchange column206
 IPTG. *See* Isopropyl β-D-thiogalactopyranoside (IPTG)
 IRES. *See* Internal ribosome entry site (IRES)
 Isogenization24
 Isopropyl β-D-thiogalactopyranoside (IPTG) 195, 197, 205, 238–241
 Isothermal titration calorimetry233

J

Jag1 49, 318, 323, 341
 Jag2 49, 323, 341
 Jagged1 6, 335–337
 Jagged2 6, 328, 335–337
 Juxtacrine.....3, 335

K

Kinase.....7, 67, 328
 Klumpfuß134
 Knock-in48, 53–57
 Knock-out 49, 312, 325
 conditional49
 Knockout Mouse Project (KOMP)49

L

LacZ. *See* β-Galactosidase
 LAMP-195
 Lateral inhibition..... 3, 285, 287–300, 302–307
 LCI. *See* Luciferase complementation imaging (LCI)
 Learning and memory128
 Ligand
 binding domain 8, 324, 326
 dependent 9, 145, 147, 149, 151, 158, 163, 164
 independent 8, 9, 133, 147, 149, 152, 158, 163–166, 324, 341
 receptor complex.....5–8
 selectivity4, 6
 Ligand-Fc..... 147, 148, 151, 152, 158, 159, 161, 164, 166, 167
 Lin-122
 Lineage analysis.....47
 Lin-12/Notch repeat (LNR) 6, 9, 32
 Liquid chromatograph linked to tandem mass spectrometer (LC-MS/MS).....210
 Loss-of-function 16–18, 20, 24, 30, 48–53, 248, 337–339
 Loss of heterozygosity (LOH)56
 LoxP sites 48, 50, 51, 53
 Luciferase
 assay (*see* Assay)
 click beetle green (CBG) 156, 159, 161, 166
 firefly138, 144, 150, 166, 170, 325–329, 331, 338
 Renilla135, 138, 139, 150, 162, 325–329, 331, 338, 341
 Ub-Luc.....170, 171
 Luciferase complementation imaging (LCI)155–168
 Luciferase fragments155–157
 Nluc, CLuc.....155, 156
 Luciferin
 coelenterazine 162, 325, 328, 332
 D-luciferin.....148, 159, 161, 162, 164, 166, 167, 171, 172, 174, 176, 177, 326

Lysis buffer135, 148, 150–152, 183,
186, 187, 195, 197, 198, 239–241, 259–261,
263–265, 278, 280, 328, 331

Lysosomal pathway.....87

Lysosome..... 8, 65, 95

M

MACS analysis. *See* Model based Analysis for ChIP-Seq
(MACS) analysis

MAML. *See* Mastermind-like (MAML)

Mastermind (Mam)..... 2, 4, 7, 9, 106, 133, 231, 256, 324

Mass spectral (MS) analysis211

Mastermind-like (MAML)..... 116, 145, 147, 155–157

 DNMAML145, 147

 MAML17, 49, 231, 232, 234,
 235, 237, 241, 242, 335

 MAML27

 MAML37

Mathematical modeling.....286, 303

Mathematical view9

Matlab 286, 289, 290

MCS. *See* Multiple cloning site (MCS)

β -Mercaptoethanol (β ME).....238

Methyltransferase255

Microarray.....270

Micrococcal nuclease (MNase).....257, 259, 261, 265, 273

Micro RNA (miRNA).....16

Mifepristone (RU486).....48

Mindbomb (Mib).....5, 6

Mitotic recombination.....17

MNase. *See* Micrococcal nuclease (MNase)

Model based Analysis for ChIP-Seq (MACS)
 analysis..... 267, 268, 270, 274

Model organisms2, 9, 15, 30, 181, 184

Modifications 4, 7, 8, 10, 29–32, 36, 41, 43,
 45, 88, 151, 194, 209–220, 256–258, 269, 277

Modifier screen.....16

Morphogen.....286, 304–307

Morphogenesis3

Mosaic 18, 65, 85

Mosaic analysis with repressible cell marker
 (MARCM).....106

Mosaicism18

Motif search268–269, 275

Mouse (mice). *See* *Mus musculus*

Mouse Genome Informatics (MGI) database49, 58

Multiple cloning site (MCS).....33, 34, 36, 104, 133

Mus musculus..... 3, 9, 30, 31, 47–59, 63, 69, 72,
 74, 80, 83, 89, 115–128, 169–177, 210–213,
 216–219, 312, 317–319, 325, 336–339, 341

Mutagenesis..... 16–22, 24, 34, 36, 38, 48, 49, 194, 203

Mutations..... 2, 9, 16–19, 22–25, 29–34, 36–43,
 45, 48–50, 58, 143, 157, 248, 256, 317, 324, 325

N

N1. *See* Notch1 (N1)

N-acetyl-cysteine (NAC)172, 176

NAS. *See* Notch Activity Sensor (NAS)

Negative regulatory region (NRR) 6, 9, 323–328

Nervous system..... 2, 4, 23, 127

Neuralized (Neur)5, 6, 79

Neural stem cell.....169–172, 174–176, 178, 325

Neurogenic2, 312

Neutralizing antibodies336

 Demcizumab (OMP-21M18).....336

 Enoticumab (REGN421).....336

 YW152F.....336

Neutral loss..... 211, 216–219

NEXT. *See* Notch extracellular truncation (NEXT)

NICD. *See* Notch intracellular domain (NICD)

N,N,N',N'-tetramethylethylenediamine
 (TEMED).....235, 237

Notch1 (N1)..... 9, 49, 55–57, 88, 90, 115, 117,
 118, 159, 160, 211–213, 216–219, 224, 225, 232,
 235, 239, 247, 251, 267–272, 275, 312, 315–318,
 324–326, 331, 338

Notch2..... 49, 56, 57, 145, 159, 324, 325

Notch3..... 49, 247, 251, 315, 316, 319, 324–327

Notch4..... 56, 316, 325, 338

Notch Activity Sensor (NAS)54, 58

Notch extracellular truncation (NEXT) 5, 7, 8

Notch intracellular domain (NICD) 3–9, 53, 63–65,
 69, 101, 116, 117, 131–135, 137–141, 144, 148,
 155–157, 162, 169, 223–229, 231, 248, 256, 257,
 285, 311, 312, 315, 323, 331, 335, 340

Notch intracellular Green Fluorescent Protein
 (N-iGFP)81

Notch/Notch receptor

 cleavage..... 7, 8, 146, 156, 223, 248, 286,
 300, 312, 316, 317, 323, 324

 Cre fusion55–56, 58

 hNotch-1_{11–13} 194, 195, 201, 204

 localization..... 57, 64, 65, 68

 Notch Δ E/mNotch Δ E..... 144, 224–228

 Notch extracellular domain (NECD)..... 6, 8, 32,
 63, 69, 89, 107, 248

 NotchFL..... 152, 158, 160, 161, 164, 167

 RAMANK231, 232, 234, 235,
 237, 239, 240, 243

 signaling 1–10, 16, 18, 20,
 30, 31, 41–43, 47–59, 79, 87, 88, 101–111, 115, 117,
 118, 127, 128, 131–141, 143–146, 152, 155, 157,
 169–178, 182, 223, 231–243, 247–249, 252, 255,
 256, 258, 285–307, 311–319, 323–332, 335–341

Notch reporter

 TP1..... 144, 147, 329

 4XCSL 144, 146, 326

- Notch responsive element (NRE) 102, 103, 105, 118, 127, 133, 134
- Notch signaling
 canonical..... 3–5, 9, 335
 non-canonical..... 3, 4, 49
 targets 7, 9, 49, 247, 249, 252, 255, 286, 340
- Notum dissection..... 71, 83
- NRE. *See* Notch responsive element (NRE)
- NRR. *See* Negative regulatory region (NRR)
- N-terminal domain (NT domain)..... 203, 232, 335
- N-terminus (amino-terminus)..... 4, 331
- Nuclear complexes..... 7, 9, 231–243
- Nuclear import 7, 10
- Nuclear localization sequence (NLS) 6, 7, 54
- Nuclear magnetic resonance (NMR)/NMR spectroscopy..... 193–195, 197, 201–205, 207
- Nuclear translocation..... 6, 157, 249
- Nucleofection 337, 340
- Nucleus..... 2–5, 7, 8, 10, 101, 131, 132, 169, 231, 311, 324, 325, 335
- Null, null allele 41–43, 49–51, 56
- Numb 79–81
- O**
- O-fucose 5, 210, 211, 216–218
- O-fucosylation 4, 216
- O-fucosyltransferase 1 (*O*-fut1) (*Pofut1*)..... 4, 5, 210
- O-glucose 31, 210, 211, 216, 218, 219
- O-glucosylation 4, 31, 32
- O-glucosyltransferase 1 (*Poglut1*). *See* Rumi
- O-linked glucose..... 31
- O-N-Acetylglucosamine (*O*-GlcNAc) 4, 209, 210
- Open reading frame (ORF)..... 184, 190
- oriV. *See* Conditionally amplifiable origin of replication (oriV)
- Oscillatory expression..... 170
- O-xylose..... 4
- P**
- Paracrine..... 3
- Paraformaldehyde (PFA)..... 69, 70, 80, 90, 97, 122
- Paralog..... 4, 15, 115, 146, 156, 194
- Pattern formation 18
- PCR 38, 39, 44, 137.
See also Quantitative PCR (qPCR); Quantitative real-time PCR (RT-QPCR)
- P* element
 meiotic mapping..... 24
 transgenesis..... 30, 33
- Permeabilization..... 68, 76, 89, 99
- PEST (proline (P)/glutamic acid (E)/serine (S)/threonine (T)-rich motif) 6, 7, 9, 105, 224
- Phage attachment site (attP) 33, 39, 41, 44
- Phalloidin 65, 69, 72
- PhiC31 (Φ C31)
 integrase..... 39, 44
 mediated transgenesis..... 33, 38, 39
 site-specific genomic integration 31
- Phosphate-buffered saline (PBS) 69–73, 75, 76, 80, 83, 88–97, 107–109, 118, 122, 132, 134, 136, 148, 150–152, 159, 161, 162, 167, 173–177, 83, 186, 187, 190, 212, 226, 249, 250, 263, 264, 328–332, 337–339
- Phosphorylation 7, 223, 224
- Poisson distribution..... 22
- Polycomb complex..... 256
- Post-translational modification
 glycosylation 8, 209
 hydroxylation 209
 phosphorylation..... 7
 ubiquitination 7, 209
- PRC2..... 256
- Presomitic mesoderm (PSM) 170, 172–174
- Prokaryotic protein expression..... 193
- Proliferation..... 3, 18, 169, 319
- Proteasome 6, 7, 9, 10, 228
- Proteasome inhibitor
 lactacystin 225, 228
- Protein
 purification 195–196, 233, 234, 238–239
- Protein complementation assay (PCA)..... 155
- Protein–protein interaction. *See* Interaction
- Protein tag
 alkaline phosphatase (AP) 278–281, 283
 FLAG..... 185, 190, 274, 281
 GST..... 239, 243
 hemagglutinin (HA)..... 89, 96, 183, 185–188, 190, 191
 His..... 200, 206, 207, 211–213, 220, 239
 Myc 211, 212, 224
- Proteolytic cleavage 2, 6, 7, 55, 56, 285, 286
- Proteome 181, 182, 184
- Proteomics..... 181–191, 220
- PSM. *See* Presomitic mesoderm (PSM)
- Pulling force 6
- Pulse labeling..... 88
- Q**
- Quality control 188, 190
- Quantitative..... 9, 133, 146, 157, 159, 167, 210, 211, 225, 234, 277
- Quantitative PCR (qPCR)..... 132, 135, 137, 139, 249, 251, 264, 274, 339
- Quantitative real-time PCR (RT-QPCR)..... 132, 137, 249
- R**
- Rab GTPases/Rab 85
 rab5..... 95
- RAM (RBP-jk Associated Molecule) 7

RBPj.....49, 54, 55, 231, 248
 RBP-jk (Recombination signal binding protein for immunoglobulin kappa J region) 115, 128, 155–157, 162, 335, 337
 Real time PCR (RT-PCR)..... 132, 135, 257
 Receptor
 activation4, 6, 101, 144, 156, 324
 ligand binding.....8, 328
 notch (*see* Notch/Notch receptor)
 Recombinant
 ligands 328, 330, 331
 protein 193, 195, 197, 201
 Recombineering 31, 34–36, 38, 44
 Recycling 5, 6, 79, 87, 88, 90–94, 98
 Recycling assay 91–94, 98
 Refolding.....193–207
 Reporter
 fluorescent 105, 118, 143–145, 170
 Notch activity23, 116, 118, 122, 124
 Reverse-transcription136, 137
 RNA interference (RNAi)..... 16, 106, 132, 282
 Room temperature (RT)..... 43, 51, 70, 72, 81, 93–97, 99, 108, 109, 136, 138, 140, 150–152, 164, 175–177, 185–187, 190, 198, 200, 213–215, 226, 228, 229, 236, 239, 242, 262, 263, 266, 279–282, 329, 331
 ROSA26..... 49, 53
 RU486. *See* Mifepristone (RU486)
 Rumi.....4, 5, 31, 33, 36–38, 210

S

Sanpodo (Spdo).....79–81
 SDS-PAGE. *See* Gel electrophoresis (protein)
 γ -Secretase inhibitor (GSI)
 Begacestat316
 BMS-906024.....315
 compound E (CmpdE).....315, 328
 DAPT 116, 117, 145, 163, 249, 313, 315, 318, 328, 330, 337, 338
 Dibenzazepine (DBZ).....315–318
 L-685,458..... 314, 318
 LY-411575.....312
 MCL 28170312
 MG132.....312
 MRK-003.....313, 314, 316, 318, 319
 MRK-0752.....316
 MW167, GSI II 312, 314, 318
 PF-03084014.....316, 317
 RO4929097313–315
 Z-IL-CHO314
 Segmentation clock170
 Selectivity4, 6, 207, 315, 316
 Sensory organ precursor (SOP)..... 79, 81, 102
 Serrate2, 5, 6, 133, 210, 277, 278, 323, 335

Signal
 activation6–8, 68, 87, 131, 338, 340
 receiving cell 3, 5, 8, 87
 sending cell 5, 6, 8, 87
 sequence..... 4, 6, 212, 224
 termination6, 7
 Simulation286, 287, 289, 293, 297, 298, 303–305
 Single nucleotide polymorphism (SNP).....24
 Site-directed mutagenesis..... 36, 38, 203
 Site-specific integration.....31, 32
 Small interfering RNA (siRNA)96, 98
 SNP. *See* Single nucleotide polymorphism (SNP)
 Sodium 2-mercaptoethanesulfonate (MesNa).....89–94
 Somite 170, 173, 178
 SOP. *See* Sensory organ precursor (SOP)
 Split 23, 71, 110, 137, 140, 248, 263, 273
 Stem cell 21, 54, 79, 169–172, 174–176, 178, 325
 Stereomicroscope..... 19, 45, 69, 80, 81
 Stroke1
 Structure-function analysis..... 10, 29–45, 47, 56, 143–145, 156, 161
 Suppressor of Hairless (Su(H)) 2, 7, 102, 115, 133, 134, 324
 Synaptic plasticity.....3
 Synthetic transcriptional reporter 101, 102

T

TAD. *See* Transactivation domain (TAD)
 Tamoxifen..... 48–53, 56
 TAN-1.....2
 Target identification 247, 248, 252
 TEMED. *See* *N,N,N,N*-tetramethylethylenediamine (TEMED)
 Tetracycline (Tet) 158, 160, 165, 167
 Tetramethylrhodamine B isothiocyanate (TRITC).....69, 72
 TEV. *See* Tobacco etch virus protease (TEV)
 Thioglycolic acid19
 Three-dimensional structure194, 204
 Tobacco etch virus protease (TEV)238–243
 Trafficking. *See* Intracellular, trafficking
 Transactivation domain (TAD)6, 7
 Transcription/transcriptional
 activator 55, 103, 146
 regulation.....7
 reporter143–153
 repressor.....169, 256
 Transfection
 lipofection.....340
 nucleofection337, 340
 Transgenic
 fly.....30, 81
 mouse 47, 120, 127, 170

Transgenic Notch Reporter (TNR).....54
Trans-interactions.....288, 301, 307
 Transition-state analogs.....314
 Translation.....6, 57, 224, 252, 324
 Transmembrane domain (TMD)2, 6, 57, 157,
 159, 312, 323
 Transposable element/transposon.....16
 β -Trefoil domain (BTD).....231, 232
 TRITC. *See* Tetramethylrhodamine B isothiocyanate
 (TRITC)
 TritonX-100 with PBS (PBT).....69, 70
 Type-I transmembrane protein.....4, 6

U

UAS. *See* Upstream activating sequences (UAS)
 Ubiquitination
 mono-.....6
 poly-.....7
 Ubiquitin-proteasome system.....9
 UCSC genome browser.....267, 268, 274
 Ultrabithorax (Ubx).....18
 Universal Proteomics Resources.....184
 Untranslated region (UTR)
 3'UTR35, 57,
 170, 171
 5'UTR170, 171
 Upstream activating sequences (UAS).....16, 146, 327
 UTR. *See* Untranslated region (UTR)

V

Vasculature48, 123, 316
 Vesicle/vesicular trafficking

endocytosis6
 exocytosis.....6
 ligand6
 receptor.....6
 recycling.....6

W

Western blotting/blot91–94, 119, 182, 185,
 186, 190, 207, 225–228, 283, 331
 Whole-exome sequencing (WES).....10
 Whole genome sequencing.....24
 Whole-mount immunohistochemistry.....68
 Wild-type.....17, 18, 24,
 30, 32–36, 38–42, 45, 54, 65, 121, 127,
 170, 226, 235, 317

Wing

 notch/notching1, 2, 105
 vein1, 39, 41, 42, 45

Worm. *See* *Caenorhabditis elegans*

X

Xenopus.....6
 X-gal staining106, 108, 109, 111
 X-ray crystallography.....193, 233
 Xylosyltransferase210

Y

Yeast-two-hybrid (Y2H)182

Z

Zebrafish312